Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone®

Journal of Neuroimmunology

Volumn 115, Issue 1-2, 2001, Pages 152-160

  Brenner, Talma ^a   Arnon, Ruth ^b   Sela, Michael ^b   Abramsky, Oded ^a   Meiner, Zeev ^a   Riven Kreitman, Rivka ^c   Tarcik, Nora ^c   Teitelbaum, Dvora ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c TEVA PHARMACEUTICALS   (Israel)

Author keywords

Anti Cop1 antibodies; Copolymer 1; Glatiramer acetate; IgG1 IgG2; T cell proliferation; Th1 Th2

Indexed keywords

GLATIRAMER; IMMUNOGLOBULIN G; MYELIN BASIC PROTEIN;

ADULT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RELAPSE; TH2 CELL;

ADULT; ANTIBODY AFFINITY; CELL DIVISION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; MALE; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; PEPTIDES; RECURRENCE; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 0035795018     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(01)00250-8     Document Type: Article

References (40)

1. T-suppressor hybridomas and IL-2 dependent lines induced by copolymer 1 or by spinal cord homogenate downregulate experimental allergic encephalomyelitis
2. Copolymer 1 induces T cells of the T-helper type 2 that crossreact with myelin basic protein and suppress experimental allergic encephalomyelitis
3. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 induced by Copolymer 1
4. T cells responsive to myelin basic protein in patients with multiple sclerosis
5. The development of Cop1 (Copaxone®), an innovative drug for the treatment of multiple sclerosis: Personal reflections
6. Anti-ganglioside antibodies in multiple sclerosis
7. Multiple Sclerosis: An autoimmune disease of multifunctional aetiology
8. A pilot trial of Copolymer 1 in exacerbating-remitting multiple sclerosis
9. A monoclonal antibody raised to corpus callosum extract reacts with 2, 3′-cyclic nucleotide 3′-phosphohydrolase
10. Immunogenic potential of copolymer 1 in normal human lymphocytes
11. Human cellular immune response to Copolymer 1 and myelin basic protein
12. Autoreactivity to myelin antigens: Myelin oligodendrocyte glyprotein is a prevalent autoantigen
13. Glatiramer acetate (Copaxone®) induces degenerate Th2-polarized responses in patients with multiple sclerosis
14. Sustained efficacy of glatiramer acetate for injection in a 5-year trial of relapsing remitting MS
15. Cell-mediated immune response to Copolymer 1 in multiple sclerosis measured by the macrophage procoagulant activity assay
16. Immunologic mechanisms and therapy in multiple sclerosis
17. Clinical aspects of multiple sclerosis
18. Basic encephalitogenic protein: A simplified purification on sulphoethyl-sephadex
19. The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis
20. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized combined trial
21. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis
22. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
23. Predominance of autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: Reactivity to the extracellular domain of MOG is directed against three main regions
24. T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans
25. Immunological aspects of demyelinating diseases
26. Copolymer 1 in relapsing-remitting multiple sclerosis: A multi-centre trial
27. Treatment of multiple sclerosis with Copolymer-1 (Copaxone®): Implicating mechanisms of Th1 to Th2/Th3 immune-deviation
28. Effects of Copolymer 1 on human T cells in vivo and in vitro
29. Neuroimmunological diseases of animals and humans
30. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
31. The epigenetics of multiple sclerosis: Clues to etiology and a rationale for immune therapy
32. Major T cell responses in multiple sclerosis
33. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide
34. Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic Copolymer 1
35. Synthetic Copolymer 1 inhibits human T cell lines specific for myelin basic protein
36. Antibodies to Copolymer 1 do not interfere with its therapeutic effect
37. Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis
38. In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis
39. Molecular requirements involved in suppression of EAE by basic copolymers of amino acids
40. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide